stonks4u
Sign up free
ATNM logo

ATNM Actinium Pharmaceuticals, Inc.

New York Stock Exchange Arca · Biotechnology · Healthcare

$1.04
+0.08 (+7.90%)

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients…

Market Cap: $32.63Mwww.actiniumpharma.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

80
80
Aug 14Aug 14

Quote

Day Range
$0.94 – $1.09
52-Week Range
$0.73 – $1.81
Volume
$489.6K
Market Cap
$32.63M
50-Day Avg
$0.93
200-Day Avg
$1.18
Prev Close
$0.96
Open
$0.95

Valuation & Ratios

P/E Ratio
-1.25
EPS
$-1.09
P/B Ratio
5.42
P/S Ratio
471.40
Debt/Equity
0.22
Current Ratio
6.20
Dividend Yield
+0.0%
Gross Margin
+100.0%

Returns & Efficiency

Return on Equity
-432.6%
Return on Assets
-65.5%
FCF Yield
-58.2%
EV/EBITDA
0.12

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$90.0K$-33.89M$-1.09
2024$0.00$-38.24M$-1.27
2023$81.0K$-48.82M$-1.83
2022$1.03M$-33.02M$-1.37
2021$1.14M$-24.77M$-1.20

Social Signal Score

30
5d
30
1 mentions
—
30d
30
1 mentions
—
60d
30
1 mentions
—
90d
30
1 mentions
—
news: 1

Earnings

Fri, Nov 13(in 3 months)

Consensus estimate $-0.27 per share

5of 7 quarters beat consensus

Typical surprise +31.3% (median, so one quarter with a near-zero estimate can't distort it)

  • Fri, Aug 7$0.89 vs $-0.20beat
  • Fri, May 8$-0.18 vs $-0.22beat
  • Mon, Mar 30$-0.19 vs $-0.19miss
  • Fri, Nov 14$-0.16 vs $-0.25beat
  • Fri, Aug 8$-0.22 vs $-0.32beat
  • Fri, May 9$-0.51 vs $-0.26miss

Estimates and results for ATNM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

ATNMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsprnewswire.com·22h ago·Negative

    … Property and Manufacturing Advances and Provides NYSE American Listing Update NEW YORK, Aug. 14, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents adding to a broad suite of IP, and expansion of the Company's manufacturing capacity, as the program approaches clinical milestones from the fourth quart…

    View source ↗